Herbalife Ltd header image

Herbalife Ltd

HLF

Equity

ISIN KYG4412G1010 / Valor 2002103

CTA NASDAQ OMX Stock Exchange (2024-09-18)
USD 7.01-1.20%

Herbalife Ltd
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Herbalife Ltd is a global health and wellness company that offers a variety of science-based products, including weight management, supplements, and personal care items, designed to promote a healthy lifestyle. These products are distributed exclusively through Herbalife Independent Distributors, who provide personalized coaching and motivation to help customers achieve their health goals. Herbalife operates multiple innovation and manufacturing facilities worldwide, focusing on personalization and working closely with their distributors to meet customer needs. The company's product line includes meal replacement shakes, teas, supplements, sports hydration, and personal care products. Herbalife also has a Global Consumer Safety team available to address any product-related inquiries from healthcare providers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Net Sales

Herbalife Ltd. reported net sales of $1.3 billion for the second quarter of 2024, reflecting a 2.5% decrease compared to the same period in 2023. This decline was primarily due to 270 basis points of foreign exchange headwinds. However, on a constant currency basis, net sales saw a slight increase of 0.2% year-over-year, driven by growth in Latin America, EMEA, and Asia Pacific regions.

Net Income

For the second quarter of 2024, Herbalife Ltd. achieved a net income of $4.7 million. When adjusted for certain items, the adjusted net income was significantly higher at $54.8 million. The company faced headwinds from restructuring program expenses and a loss on extinguishment of debt, which impacted the reported net income figures.

Adjusted EBITDA

Herbalife Ltd.'s adjusted EBITDA for the second quarter of 2024 was $180.0 million, surpassing the company's guidance. This figure represents a year-over-year increase in the adjusted EBITDA margin by 120 basis points, reaching 14.1%. The company attributed this performance to improved operational efficiencies and cost management.

Cash Flow and Capital Expenditures

During the second quarter of 2024, Herbalife Ltd. generated $102.5 million in net cash from operating activities. The company also reported capital expenditures of approximately $36 million for the same period. For the full year of 2024, Herbalife expects total capital expenditures to range between $120 million and $150 million.

Outlook and Guidance

Herbalife Ltd. has provided guidance for the third quarter of 2024 and revised its full-year 2024 outlook. The company has reduced its net sales guidance but raised its adjusted EBITDA guidance for the full year. Capital expenditures for the year are expected to remain within the previously stated range, reaffirming the company's commitment to strategic investments.

Summarized from source with an LLMView Source

Key figures

-51.6%1Y
-84.2%3Y
-82.9%5Y

Performance

65.4%1Y
60.3%3Y
54.4%5Y

Volatility

Market cap

1821 M

Market cap (USD)

Daily traded volume (Shares)

206,523

Daily traded volume (Shares)

1 day high/low

7.37 / 6.99

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%EUR 35.10
Formycon AG
Formycon AG Formycon AG Valor: 12194189
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.10%EUR 49.35
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.35%EUR 1.74
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.18%SEK 237.80
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.88%SEK 68.70
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.59%SEK 170.30
Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.15%SEK 663.00
4basebio PLC
4basebio PLC 4basebio PLC Valor: 112829117
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 17.10
Cassava Sciences Inc
Cassava Sciences Inc Cassava Sciences Inc Valor: 46983284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.13%USD 30.32
Stryker Corp
Stryker Corp Stryker Corp Valor: 974330
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.71%USD 361.36